<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">OKADA, TAKURO</style></author><author><style face="normal" font="default" size="100%">MATSUKI, TAKASHI</style></author><author><style face="normal" font="default" size="100%">FUSHIMI, CHIHIRO</style></author><author><style face="normal" font="default" size="100%">OKAMOTO, ISAKU</style></author><author><style face="normal" font="default" size="100%">SATO, HIROKI</style></author><author><style face="normal" font="default" size="100%">KONDO, TAKAHITO</style></author><author><style face="normal" font="default" size="100%">TOKASHIKI, KUNIHIKO</style></author><author><style face="normal" font="default" size="100%">ITO, TATSUYA</style></author><author><style face="normal" font="default" size="100%">MASUBUCHI, TATSUO</style></author><author><style face="normal" font="default" size="100%">TADA, YUICHIRO</style></author><author><style face="normal" font="default" size="100%">MIURA, KOUKI</style></author><author><style face="normal" font="default" size="100%">HANYU, KENJI</style></author><author><style face="normal" font="default" size="100%">OMURA, GO</style></author><author><style face="normal" font="default" size="100%">TAKAHASHI, HIDEKI</style></author><author><style face="normal" font="default" size="100%">YAMASHITA, TAKU</style></author><author><style face="normal" font="default" size="100%">ORIDATE, NOBUHIKO</style></author><author><style face="normal" font="default" size="100%">TSUKAHARA, KIYOAKI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4907-4912</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.15996</style></doi><volume><style face="normal" font="default" size="100%">42</style></volume><issue><style face="normal" font="default" size="100%">10</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p&gt;0.99, p=0.11, and p&gt;0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC.</style></abstract></record></records></xml>